Provided by Tiger Fintech (Singapore) Pte. Ltd.

Ascendis Pharma A/S

157.20
-4.3200-2.67%
Post-market: 157.200.00000.00%16:36 EDT
Volume:287.11K
Turnover:45.32M
Market Cap:9.49B
PE:-24.98
High:165.26
Open:161.78
Low:156.28
Close:161.52
Loading ...

JPMorgan ups Ascendis target, sees buying opportunity on pullback

TIPRANKS
·
29 Jan

J.P. Morgan Sticks to Their Buy Rating for Ascendis Pharma (ASND)

TIPRANKS
·
29 Jan

Is Ascendis Pharma (ASND) the High Growth International Stock to Invest in Now?

Insider Monkey
·
23 Jan

European Equities Traded in the US as American Depositary Receipts Edge Lower in Wednesday Trading

MT Newswires Live
·
23 Jan

BioMarin Pharmaceutical Sues Ascendis Pharma for Patent Infringement in Germany

MT Newswires Live
·
14 Jan

BioMarin initiates legal action against Ascendis over patent infringement

TIPRANKS
·
14 Jan

BioMarin Announces Legal Action Against Ascendis Pharma A/S in European Unified Patent Court

PR Newswire
·
14 Jan

European Equities Traded in the US as American Depositary Receipts Start Week Lower in Monday Trading

MT Newswires Live
·
14 Jan

Evercore ISI Remains a Buy on Ascendis Pharma (ASND)

TIPRANKS
·
13 Jan

Morgan Stanley Remains a Hold on Ascendis Pharma (ASND)

TIPRANKS
·
13 Jan

Ascendis Pharma (ASND) Receives a Buy from Stifel Nicolaus

TIPRANKS
·
13 Jan

Ascendis Pharma Initiated at Buy by UBS

Dow Jones
·
07 Jan

Ascendis Pharma initiated with a Buy at UBS

TIPRANKS
·
07 Jan

Bank of America Securities Sticks to Their Buy Rating for Ascendis Pharma (ASND)

TIPRANKS
·
07 Jan

European Equities Traded in US as American Depositary Receipts Surge on Monday

MT Newswires Live
·
07 Jan

Analysts Offer Insights on Healthcare Companies: Pharvaris (PHVS), Ascendis Pharma (ASND) and BioNTech SE (BNTX)

TIPRANKS
·
02 Jan

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Axsome Therapeutics (AXSM) and Ascendis Pharma (ASND)

TIPRANKS
·
30 Dec 2024

Leerink Partners Keeps Their Buy Rating on Ascendis Pharma (ASND)

TIPRANKS
·
25 Dec 2024

Sage Therapeutics (SAGE) Surges 12.2%: Is This an Indication of Further Gains?

Zacks
·
23 Dec 2024

Ascendis Pharma announces commercial availability of YORVIPATH in U.S.

TIPRANKS
·
19 Dec 2024